Breakthroughs in next-generation vaccine technologies are reshaping immunization with unprecedented speed and precision. Self-amplifying RNA, circular RNA, viral replicons, and nanoparticle-based carriers are pushing the boundaries of immune engineering. These platforms offer benefits like dose sparing, rapid development, thermostability, and targeted delivery. Researchers are also exploring microneedle patches, oral formulations, and implantable devices to improve accessibility and compliance. Integration with AI-driven antigen design and immunoinformatics accelerates the transition from concept to clinic. Next-generation vaccine technologies are particularly promising for rapidly mutating pathogens and individualized immunotherapies. Their success depends on interdisciplinary collaboration across material science, molecular biology, and digital health. As innovation accelerates, these technologies stand to revolutionize global vaccine development and distribution.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States